BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29753750)

  • 1. New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and apoptosis.
    Tian QT; Ding CY; Song SS; Wang YQ; Zhang A; Miao ZH
    Biochem Pharmacol; 2018 Aug; 154():255-264. PubMed ID: 29753750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
    Kassab AE; Gedawy EM
    Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer Cells.
    Wu CC; Huang KF; Yang TY; Li YL; Wen CL; Hsu SL; Chen TH
    PLoS One; 2015; 10(7):e0132052. PubMed ID: 26147394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way.
    Xie J; Liu JH; Liu H; Liao XZ; Chen Y; Lin MG; Gu YY; Liu TL; Wang DM; Ge H; Mo SL
    BMC Cancer; 2016 Nov; 16(1):899. PubMed ID: 27863471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.
    Zhuo ST; Li CY; Hu MH; Chen SB; Yao PF; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
    Org Biomol Chem; 2013 Jun; 11(24):3989-4005. PubMed ID: 23657605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase IIα: Induction of G2 phase arrest in human gastric cancer cells.
    Hikita K; Yamakage Y; Okunaga H; Motoyama Y; Matsuyama H; Matsuoka K; Murata T; Nakayoshi T; Oda A; Kato K; Tanaka H; Asao N; Dan S; Kaneda N
    Bioorg Med Chem; 2021 Jan; 30():115904. PubMed ID: 33341500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
    Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
    Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile.
    Khalil OM; Gedawy EM; El-Malah AA; Adly ME
    Bioorg Chem; 2019 Mar; 83():262-276. PubMed ID: 30391699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Synthesis of Arylnaphthalene Lignan Lactone Derivatives as Potent Topoisomerase Inhibitors.
    Chen W; Feng Z; Hu D; Meng J
    Med Chem; 2021; 17(8):856-865. PubMed ID: 32520691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.
    Yao BL; Mai YW; Chen SB; Xie HT; Yao PF; Ou TM; Tan JH; Wang HG; Li D; Huang SL; Gu LQ; Huang ZS
    Eur J Med Chem; 2015 Mar; 92():540-53. PubMed ID: 25599951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorinated 3,6,9-trisubstituted acridine derivatives as DNA interacting agents and topoisomerase inhibitors with A549 antiproliferative activity.
    Nunhart P; Konkoľová E; Janovec L; Jendželovský R; Vargová J; Ševc J; Matejová M; Miltáková B; Fedoročko P; Kozurkova M
    Bioorg Chem; 2020 Jan; 94():103393. PubMed ID: 31679839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
    My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
    Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
    Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
    Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of the anticancer effect of doxorubicinin drug-resistant gastric cancer cells by tanshinone IIA.
    Xu Z; Chen L; Xiao Z; Zhu Y; Jiang H; Jin Y; Gu C; Wu Y; Wang L; Zhang W; Zuo J; Zhou D; Luan J; Shen J
    Phytomedicine; 2018 Dec; 51():58-67. PubMed ID: 30466628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
    Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
    Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation.
    Kolb RH; Greer PM; Cao PT; Cowan KH; Yan Y
    PLoS One; 2012; 7(11):e50281. PubMed ID: 23166842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quercetin-3-O-glucoside induces human DNA topoisomerase II inhibition, cell cycle arrest and apoptosis in hepatocellular carcinoma cells.
    Sudan S; Rupasinghe HP
    Anticancer Res; 2014 Apr; 34(4):1691-9. PubMed ID: 24692698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
    Patra N; De U; Kang JA; Kim JM; Ahn MY; Lee J; Jung JH; Chung HY; Moon HR; Kim HS
    Eur J Pharmacol; 2011 May; 658(2-3):98-107. PubMed ID: 21376033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds.
    Janočková J; Plšíková J; Kašpárková J; Brabec V; Jendželovský R; Mikeš J; Kovaľ J; Hamuľaková S; Fedoročko P; Kuča K; Kožurková M
    Eur J Pharm Sci; 2015 Aug; 76():192-202. PubMed ID: 25960253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.